192.97 USD
-3.11 (-1.59%)
192.97 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 86% to LGND. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 248.31. This target is 28.68% above the current price.
- LGND was analyzed by 14 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about LGND.
- In the previous month the buy percentage consensus was at a similar level.
- LGND was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-10 | Stifel | Maintains | Buy -> Buy |
| 2025-12-09 | Citigroup | Initiate | Buy |
| 2025-11-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-07 | Benchmark | Maintains | Buy -> Buy |
| 2025-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-02 | Benchmark | Maintains | Buy -> Buy |
| 2025-08-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-10 | Stifel | Initiate | Buy |
| 2024-12-23 | Benchmark | Reiterate | Buy -> Buy |
| 2024-12-16 | Barclays | Maintains | Overweight -> Overweight |
| 2024-12-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-08 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-11-08 | Benchmark | Maintains | Buy -> Buy |
| 2024-11-08 | Barclays | Maintains | Overweight -> Overweight |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-28 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-03 | Oppenheimer | Initiate | Outperform |
| 2024-08-12 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-12 | Benchmark | Maintains | Buy -> Buy |
| 2024-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
LIGAND PHARMACEUTICALS / LGND FAQ
What is the average price target for LIGAND PHARMACEUTICALS (LGND) stock?
14 analysts have analysed LGND and the average price target is 248.31 USD. This implies a price increase of 28.68% is expected in the next year compared to the current price of 192.97.
What is the consensus rating for LGND stock?
The consensus rating for LIGAND PHARMACEUTICALS (LGND) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.